血清催化铁与慢性肾脏病进展:ICKD研究
该研究基于印度慢性肾脏病(ICKD)队列2002例轻中度CKD患者,检测基线血清催化铁(SCI)等铁代谢指标,中位随访12.6个月发现SCI升高与主要肾脏终点(MAKE)风险独立相关,提示SCI可能作为风险标志物和治疗靶点。
要点
- SCI从25th升至75th百分位,MAKE风险增加78%(43-122%)。
- SCI与MAKE的关联独立于eGFR、uACR及传统危险因素。
- SCI或可作为CKD进展的风险标志物,尚需外部验证。
核心结论
- 在轻中度CKD患者中,血清催化铁(SCI)与复合主要肾脏终点(MAKE)强烈且独立相关。
研究设计与样本
- 印度慢性肾脏病(ICKD)队列研究,纳入2002例至少有一次随访的CKD患者,检测基线铁代谢指标,中位随访12.6个月。
主要发现
- 随访期间280例(14%)发生复合MAKE。
- 调整年龄和性别后,SCI从25th升至75th百分位与MAKE风险增加78%(43-122%)相关。
- 转铁蛋白饱和度、铁蛋白和铁调素从25th升至75th百分位分别与MAKE风险增加34%(10-62%)、57%(24-100%)和74%(35-124%)相关。
- 进一步调整职业暴露、高血压、糖尿病、烟草、酒精、AKI史、基线eGFR和uACR后,SCI仍与MAKE和肾衰竭相关。
临床怎么用
- 对轻中度CKD患者,可考虑检测血清催化铁以辅助风险分层。
- SCI作为治疗靶点尚需其他研究确认,目前不应据此改变治疗。
局限性
- 研究仅基于印度队列,结论外推需谨慎。
- SCI作为治疗靶点尚需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The non-transferrin bound catalytic iron moiety catalyses production of toxic reactive oxygen species and is associated with adverse outcomes. We hypothesized that serum catalytic iron (SCI) is associated with progression of chronic kidney disease (CKD). METHODS: Baseline samples of the Indian Chronic Kidney Disease participants with at least one follow up visit were tested for total iron, iron binding capacity, transferrin saturation, SCI, ferritin and hepcidin. SCI was measured using the bleomycin-detectable iron assay that detects biologically active iron. Association with the incidence of major kidney endpoints, (MAKE, a composite of kidney death, kidney failure or > 40% loss of eGFR) was examined using Cox proportional hazards model adjusted for sex and age. RESULTS: 2002 subjects (49.9 ± 11.6 years, 68.1% males, baseline eGFR 41.01 ml/min/1.73m2) were enrolled. After a median follow up of 12.6 (12.2, 16.7) months, the composite MAKE occurred in 280 (14%). After adjusting for age and sex, increase from 25th to 75th percentile in SCI, transferrin saturation, ferritin and hepcidin were associated with 78% (43-122%), 34% (10-62%), 57% (24-100%) and 74% (35-124%) increase in hazard of MAKE, respectively. SCI was associated with MAKE and kidney failure after adjustment for occupational exposure, hypertension, diabetes, tobacco, alcohol use, history of AKI, baseline eGFR, uACR, and allowing baseline hazard to vary by centre. CONCLUSIONS: SCI is strongly and independently associated with composite MAKE in patients with mild to moderate CKD. Confirmation in other studies will allow consideration of SCI as a risk marker and treatment target.
引用
- Yadav AK, Ghosh A, Divyaveer S, et al. Serum catalytic iron and progression of chronic kidney disease: findings from the ICKD study. Nephrol Dial Transplant. 2021. PMID: 34534345. doi:10.1093/ndt/gfab271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。